Biotech Stock Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) Leads TSX Gainers on Update on Cancer Clinical Efficacy

Biotech Stock Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) Leads TSX Gainers on Update on Cancer Clinical Efficacy: Biotech Stock Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC) Leads TSX Gainers on Update on Cancer Clinical Efficacy

September Wrap-up: Stocks to Watch in Cleantech, Technology, Entertainment and Biotech (CSE: $MIDO.CN) (Nasdaq: $FTCI) (NASDAQ: $SMX) (CSE: $SOL.CN) (CSE: $WHIP.CN) (TSXV: $ZOMD.V) (NASDAQ: $SINT) (NASDAQ: $BLMZ)

 September Wrap-up: Stocks to Watch in Cleantech, Technology, Entertainment and Biotech (CSE: $MIDO.CN) (Nasdaq: $FTCI) (NASDAQ: $SMX) (CSE: $SOL.CN) (CSE: $WHIP.CN) (TSXV: $ZOMD.V) (NASDAQ: $SINT) (NASDAQ: $BLMZ)

 

 

 

 

October 4, 2024 – (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, announces today’s roundup of stocks to watch in the Cleantech, Technology, Entertainment and Biotech sectors.

 

The newest cleantech companies are involved in carbon credits, solar and digital tech that helps achieve carbon neutrality.

 

The latest tech companies include a mobile app platform, an AI-fintech and a blockchain/crypto company.

 

The newest biotech company provides advanced ceramics for medial and tech use, while the latest entertainment company manages, cultivates and promotes voice actors and VTubers.

 

Read this in full at https://www.investorideas.com/news/2024/main/10041Stocks.asp

 

Investor Ideas is always researching and searching for new stocks to add to our growing list of free stock directories. The directories are not meant as recommendations but as a research tool to discover opportunities and trading ideas in a particular sector.

 

New Stocks Added to the Cleantech Directories:

Midori Carbon Inc. (CSE:MIDO) has developed a platform to make buying and selling carbon credits easy and accessible, enabling individuals to participate in the voluntary carbon credit market, and to drive positive change for themselves and for the planet.

 

FTC Solar, Inc. (Nasdaq: FTCI) Founded in 2017 by a group of renewable energy industry veterans, FTC Solar is a leading provider of solar tracker systems, technology, software, and engineering services. Solar trackers significantly increase energy production at solar power installations by dynamically optimizing solar panel orientation to the sun. FTC Solar’s innovative tracker designs provide compelling performance and reliability, with an industry-leading installation cost-per-watt advantage.

 

SMX (Security Matters) Public Limited Company (NASDAQ:SMX) As global businesses face new and complex challenges relating to carbon neutrality and meeting new governmental and regional regulations and standards, SMX is able to offer players along the value chain access to its marking, tracking, measuring and digital platform technology to transition more successfully to a low-carbon economy.

 

New Stocks Added to the Tech Directories:

Sol Strategies Inc. (CSE:SOL) formerly Cypherpunk Holdings Inc. - is dedicated to investing in companies, cryptocurrencies, technologies, and protocols within the blockchain ecosystem. With a strategic focus on cryptocurrency and blockchain innovation, the Company leverages its extensive industry expertise to identify and support high-potential opportunities in the digital asset space.

 

Credissential Inc. (CSE:WHIP) - Formerly Impact Analytics Inc - is an AI powered financial services software developer, currently focused on the development and commercialization of its flagship product, Credissential.

 

Zoomd Technologies Ltd. (TSXV: ZOMD) (OTC: ZMDTF) established in 2012 and listed on the TSX Venture Exchange since September 2019, provides an innovative mobile app user-acquisition platform that integrates with numerous global digital media outlets. This platform presents a unified view of multiple media sources, thereby serving as a comprehensive user acquisition control center for advertisers. It streamlines campaign management through a single point of contact, simplifying customer acquisition efforts. The consolidation of media sources onto one platform enables Zoomd to offer advertisers substantial savings by reducing the need for disparate data source integration, enhancing data collection and insights, and minimizing resource expenditure.

 

New Stocks Added to the Biotech Directories:

SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops and commercializes materials, components, and technologies for medical and technical applications. SINTX is a global leader in the research, development, and manufacturing of silicon nitride, and its products have been implanted in humans since 2008. Over the past several years, SINTX has utilized strategic acquisitions and alliances to enter into new markets. The Company has manufacturing and R&D facilities in Utah and Maryland.

 

New Stocks Added to the Entertainment Directories:

BloomZ Inc. (NASDAQ: BLMZ) is a Cayman Islands holding company with an operating subsidiary, Kabushiki Kaisha BloomZ ("BloomZ Japan"), in Japan. BloomZ Japan is a Japanese audio producing and voice actor and VTuber managing company. BloomZ Japan has experienced staff who have worked on audio production for animations and video games for more than 10 years. BloomZ Japan also manages, cultivates and promotes voice actors and VTubers.

 

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for various sectors, including gaming, biotech, tech and sports. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Learn more about our news, PR and social media, podcast and ticker tag services at Investorideas.com

https://www.investorideas.com/Investors/Services.asp

 

Learn more about advertising and guest posts

https://www.investorideas.com/Advertise/

 

Follow us on Twitter (X) https://X.com/Investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com to be added to our stock directories or learn more about us

Dawn Van Zant and Cali Van Zant

 

800 665 0411

 

 

 

 

 

 

 

Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials

Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials: Biotech Stock Pasithea Therapeutics Corp. (NASDAQ: KTTA) Soars on Positive Data from Phase 1 Clinical Trials

Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD

Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD: Seelos Therapeutics, Inc. (Nasdaq: SEEL) Soars on update for its SLS-002 (intranasal racemic ketamine) for PTSD

Wave Life Sciences Ltd. (Nasdaq: WVE) Gains on Clinical Trial News

Wave Life Sciences Ltd. (Nasdaq: WVE) Gains on Clinical Trial News: Wave Life Sciences Ltd. (Nasdaq: WVE) Gains on Clinical Trial News

Stocks to Watch Battling the Opioid Epidemic; Stocks Mentioned in this article: Greenlane Holdings, Inc. (NASDAQ: $GNLN), Safe Supply Streaming Co Ltd. (CSE: $SPLY.CN), Nutriband Inc. (NASDAQ: $NTRB), QuidelOrtho Corporation (Nasdaq: $QDEL), Emergent BioSolutions Inc. (NYSE: $EBS)

  

Stocks to Watch Battling the Opioid Epidemic; Stocks Mentioned in this article: Greenlane Holdings, Inc. (NASDAQ: $GNLN), Safe Supply Streaming Co Ltd. (CSE: $SPLY.CN), Nutriband Inc. (NASDAQ: $NTRB), QuidelOrtho Corporation (Nasdaq: $QDEL), Emergent BioSolutions Inc. (NYSE: $EBS)

 

September 20, 2024 - Investorideas.com, a go-to investing platform covering cannabis stocks releases an industry snapshot looking at the battle against dangerous drugs, including fentanyl, featuring Greenlane Holdings, Inc. (NASDAQ:GNLN), one of the premier global sellers of premium cannabis accessories, child-resistant packaging, and specialty vaporization products.

 

Stocks Mentioned in this article: Greenlane Holdings, Inc. (NASDAQ:GNLN), Safe Supply Streaming Co Ltd. (CSE: SPLY), Nutriband Inc. (NASDAQ:NTRB), QuidelOrtho Corporation (Nasdaq: QDEL), Emergent BioSolutions Inc. (NYSE: EBS)

 

According to Fact.MR ,“The global opioid overdose treatment market is expected to reach a value of US$ 1.54 billion in 2024, as revealed in a new industry analysis published by proficient researchers at Fact.MR, a market research and competitive intelligence provider. Revenue from the market is projected to increase at a CAGR of 7.2% through 2034.”

 

Cannabis company Greenlane Holdings, Inc. (NASDAQ:GNLN) has entered the battle against dangerous drugs, but not only against opioids. Greenlane announced this week its plans to launch an all-new line of fentanyl, xylazine and drink spike detection test strips under the Safety Strips, Inc.  brand of drug test strips. Products will be available to order beginning September 25^th via the Company's multiple online retail storefronts, (vapor.com, puffitup.com, and higherstandards.com/) as well as its wholesale portal (wholesale.greenlane.com). Shipments will commence October 1^st.

 

In August, Greenlane announced that it had entered into a non-binding letter of intent to be the exclusive distributor in the US of Safety Strips drug detection test strips. Greenlane has been a trusted partner for some of the most successful and well-known cannabis and lifestyle brands, such as Higher Standards, Marley Natural and K.Haring, providing full sales coverage, marketing, warehousing and logistics services.

 

Paid news dissemination on behalf of GNLN

 

Read this article, featuring GNLN in full at https://www.investorideas.com/news/2024/cannabis/09201Battling-the-Opioid-Epidemic.asp

 

"We are delighted to be working with the Safety Strips' team who share our high standards for safety and quality, and our strong focus on improving people's lives and enhancing their safety," said Barbara Sher, Chief Executive Officer for Greenlane. "By combining our extensive sales, marketing, and distribution network with Safety Strips ISO 13485 validated product line of easy, fast, and accurate test strips to detect the presence of various drugs, we can do our part to help prevent accidental overdoses as well as protecting individuals from drug-induced date rape."

 

The Opioid Epidemic in the United States

According to SHADAC.ORG, "Over the past two decades, the United States has experienced a growing crisis of substance abuse and addiction that is illustrated most starkly by the rise in deaths from drug overdoses. Since 2000, the annual number of overdose deaths from any kind of drug in the U.S. has multiplied nearly six times over, rising from 17,500 to over 106,000 people in 2021. The vast majority of these deaths (about 80,000) involved some form of opioids, including heroin, prescription painkillers, and, most prevalently in recent years, synthetic opioids such as fentanyl. Fentanyl and related synthetic opioids alone accounted for roughly 71,000 drug overdose deaths in 2021, and are also involved in most methamphetamine, cocaine, and prescription opioid overdose deaths-the next most common substances associated with overdose deaths."

 

The Rising Incidence of Drink Spiking

In a January 2023 article posted on Alcohol.org, it was reported that "According to the Office on Women's Health, date-rape drugs like Rohypnol, GHB, and ketamine are used because they are not easily detected, and victims often do not remember being drugged or assaulted until many hours later. In 2016, there were over 320,000 incidents of rape and sexual assault, and these incidents are often underreported for both women and men. According to RAINN, 11.2 percent of college students experience rape or sexual assault through force, violence, or incapacitation, and in terms of drug-facilitated sexual assault, alcohol is the No. 1 substance for assailants, next to prescription drugs with tranquilizing effects and Rohypnol, ketamine, GHB, and ecstasy."

 

In response to the rising prevalence of drink spiking, the Californian Assembly passed AB 1013, July 1, 2024. The bill mandates that approximately 2400 establishments with a Type 48 license, which allows the sale of beer, wine, and distilled spirits, must display signage informing patrons that drug testing kits are available.The new law requires businesses to display signs reading, "Don't get roofied! Drink spiking drug test kits are available here. Ask a staff member for details." Establishments must offer these drug testing devices either for sale or free of charge.

 

Additionally, news came out this week from Safe Supply Streaming Co Ltd. (CSE: SPLY) noting it has made significant progress within its portfolio through Safety Strips Inc. ("Safety Strips"), as they introduce high-performing, reliable test strips designed to combat the rising dangers of fentanyl, xylazine, and drink spiking.

 

This strategic initiative is expected to create substantial value for Safe Supply shareholders, as the demand for safety and drug testing continues to grow across North America. The product launch will enter the market through the recently announced US Expansion Agreement with Greenlane Holdings, Inc. (NASDAQ:GNLN).

 

High Performing and Reliable Testing:

Safety Strips' product launch provides consumers with an affordable, easy-to-use solution for detecting fentanyl and xylazine - two substances contributing to the escalating opioid crisis. In response to new California legislation, Safety Strips' Drink Spike Test strips meet the requirements of California Assembly Bill No. 1013, passed in July 2024, which mandates that bars and clubs offer drug testing kits to their patrons. The law is aimed at reducing incidents of drink spiking, a growing safety concern in the hospitality industry.

 

Safety Strips' detection products will be available for order starting September 25, 2024, across Greenlane's online retail platforms, with shipments commencing on October 1, 2024.

 

This week Nutriband Inc. (NASDAQ:NTRB), announced a share repurchase program to buy back up to $1,000,000 of its common stock. As of September 16, 2024, the Company had 11,106,185 shares of common stock outstanding. The stock spiked over 24% on the news.

 

From the news: Progress continues on the development of AVERSA Fentanyl, with the Company maintaining its target of submitting an NDA to the FDA in Q1/Q2 2025.

 

Nutriband Inc. is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The lead product under development is an abuse deterrent fentanyl patch incorporating our AVERSA™ abuse deterrence technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

 

Earlier this year, QuidelOrtho Corporation (Nasdaq: QDEL) reported it  has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a MicroTip® Partnership Assay ("MPA"). This Fentanyl assay will help hospital and emergency room customers respond to the critical demand for enhanced opioid testing, allowing on-site fentanyl testing in less than 10 minutes to aid in immediate clinical decisions.

 

From the news: According to the Centers for Disease Control and Prevention ("CDC"), the number of fatalities resulting from fentanyl overdoses has tripled from 2016 to 2021, with an ongoing upward trend. The CDC highlights California, Florida, New York, Pennsylvania and Ohio as states with the highest mortality rates attributed to fentanyl.1 Consequently, several states have responded by implementing regulations requiring fentanyl testing to be included as a required component of drugs-of-abuse test panels.

 

"This assay transforms laboratory efficiency by integrating fentanyl testing with existing protocols to eliminate the need for external screening tests, and consolidates a lab’s drugs-of-abuse panel into a singular, streamlined system, reducing intervention time and ultimately helping to save lives," said Lily Li, Senior Director of Medical and Clinical Affairs at QuidelOrtho. "Our relentless commitment to diagnostics lies in empowering our customers with impactful assays, particularly those capable of delivering rapid drugs-of-abuse detection amidst the escalating opioid crisis."

 

From the news: Ninety percent of fentanyl is excreted as norfentanyl, which is a synthetic opioid and is not detected on standard drug screening. The ARK™ Fentanyl II Assay provides preliminary analytical test results by detecting this major metabolite, reducing the risk of false negatives. As part of QuidelOrtho’s Vitros systems’ menu of assays, the test offers clinical fentanyl testing for hospitals and emergency departments, providing an effective approach to preliminary urine drug testing.

 

From the news: Drug test results obtained in emergency departments play a crucial role in addressing unique hospital challenges. When patients test positive for opioids on a standard drug test, they’re usually directed to drug treatment programs. However, these standard tests fail to identify synthetic opioids, such as fentanyl. Without specifically testing for fentanyl, instances of fentanyl exposure might be disregarded, potentially leading to missed opportunities for life-saving interventions like administering naloxone, an opioid overdose reversal medication.

 

Although the pharmaceutical played a key role in opioid addiction, companies in the sector are building out solutions.

 

Emergent BioSolutions Inc. (NYSE: EBS) announced last month, the kicking off the second year of the Ready to Rescue initiative, which will include new college football tailgate stops, in-stadium activities, Greek Life events and student wellness clinics. As part of these expanded efforts, pro football legend and campaign spokesperson, Emmitt Smith, will continue to share his story to raise awareness of opioid risks and inspire students, parents, faculty and alumni to be prepared to save a life with NARCAN® Nasal Spray, which is available over-the-counter (OTC).

 

The Centers for Disease Control and Prevention (CDC) recently announced a reduction in drug overdose deaths for the first time since 2018.1 However, opioid poisonings continue to be the leading cause of accidental death in the United States,2 with the highest rate of opioid misuse and dependency among those 18 to 25.3 What’s more, research shows less than 15 percent of college students nationwide know how to administer naloxone,4 the active ingredient in NARCAN® Nasal Spray, which can reverse the effects of an opioid overdose, including those caused by fentanyl. Education on the dangers of fentanyl, the signs of an opioid poisoning and how to both access and administer NARCAN® Nasal Spray is vital to saving lives, particularly within college communities.

 

According to Yale Medicine, “Fentanyl isn’t new; it has been used in the U.S. since 1960 as an intravenous anesthetic. It is still prescribed today by doctors, often in the form of patches and lozenges, for treating severe and chronic pain from cancer and other illnesses and injuries.”

 

“But fentanyl has shifted from exclusively being produced by pharmaceutical companies to now also coming from drug cartels and other entities, says David Fiellin, MD, a Yale Medicine primary care physician who specializes in addiction medicine.”

 

With news that the DEA proposed rules last month to reclassify cannabis from a schedule I to a schedule III substance, the shift can now really focus on dangerous drugs Greenlane Holdings, Inc. (NASDAQ:GNLN) has the built-in marketing, warehousing and logistics services to bring Safety Strips testing for dangerous substances to the market.

 

More info in Greenlane Holdings visit here

 

Research more cannabis stocks with Investor ideas free stock directory

https://www.investorideas.com/Marijuana-Stocks/Stocks_List.asp

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more.

 

Disclaimer/Disclosure: This news article featuring GNLN is a paid for news release on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Cannabis Stocks- investing ideas in marijuana / hemp / cannabis / psychedelic stocks

Get more cannabis news, articles, podcasts and stock directories

 

Immunotherapy Clinical Trial News – Stocks to Watch; (Nasdaq: $AEMD), (NYSE: $BMY), (NYSE: $MRK), (Nasdaq: $IMRX), (NASDAQ: $IOVA), (NASDAQ: $KZIA)

 

Immunotherapy Clinical Trial News – Stocks to Watch; (Nasdaq: $AEMD), (NYSE: $BMY), (NYSE: $MRK), (Nasdaq: $IMRX), (NASDAQ: $IOVA), (NASDAQ: $KZIA)

 

September 19, 2024 - Investorideas.com, a go-to investing platform, releases the  second of a two-part series looking at news and developments for the treatment of cancer and solid tumors  focusing on immunotherapy, featuring Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections. Aethlon’s Hemopurifier® is a clinical stage immunotherapeutic device designed to combat cancer.

 

Stocks mentioned in this article: Aethlon Medical, Inc. (Nasdaq: AEMD), Bristol Myers Squibbs (NYSE: BMY), Merck & Co. (NYSE:MRK), Immuneering Corporation (Nasdaq: IMRX), Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) and Kazia Therapeutics Limited (NASDAQ: KZIA),.

 

According to News-Medical.net, “Immunotherapy, which works by enabling the body's immune system to recognize and destroy cancer cells improves long-term overall survival in patients with advanced melanoma in results from large international studies reported at ESMO 2024.  Researchers leading the longest follow-up study to date suggest that immunotherapy offers the potential for cure in patients who respond to this treatment. Further clinical trials reported at ESMO 2024 show improved long-term survival with immunotherapy given before and after surgery in women with early-stage, hard-to-treat breast cancer (triple negative breast cancer) and in patients with muscle-invasive bladder cancer.”

 

"The main message from all of these studies is that immunotherapy continues to keep its promise and hope of long-term survival for many patients with different types of cancer," said Dr. Alessandra Curioni-Fontecedro, Professor of Oncology at the University of Fribourg and Director of Oncology at the Hospital of Fribourg, Switzerland, (not involved in the study). "At ESMO 2024 we are seeing many studies in many different cancers showing that immunotherapy can work for a long time."

 

According to recent news from Aethlon Medical, Inc., “At present, approximately only 30% of cancer patients who receive pembrolizumab or nivolumab treatment for solid tumors will have lasting clinical responses to these agents. Extracellular vesicles (EVs) produced by tumors have been implicated in resistance to anti-PD-1 therapies as well as the spread of cancers. The Aethlon Hemopurifier® has been designed to bind and remove these EVs from the bloodstream, which may improve therapeutic response rates to anti-PD-1 antibodies. In preclinical studies, the Hemopurifier® has been shown to reduce the number of EVs in cancer patient plasma samples.”

Paid News Dissemination of behalf of AEMD

 

Read this article featuring AEMD in full at https://www.investorideas.com/news/2024/biotech/09191Immunotherapy-Clinical-Trials.asp

 

Following the news of cancer trials activated in Australia earlier this week, Aethlon Medical, Inc. (Nasdaq: AEMD) today announced that, on September 9, 2024, the Medanta Institutional Ethics Committee (MIEC) granted full ethics approval for Aethlon's safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Merck & Co., Inc.'s (NYSE:MRK) Keytruda® (pembrolizumab) or Bristol Myers Squibb's (NYSE: BMY) Opdivo® (nivolumab) (AEMD-2022-06 Hemopurifier® Study). The approval is valid for one year, followed by annual reviews. This trial has previously been reviewed by the Institutional Review Board at Medanta. Additionally, the company previously received a No Objection Certificate (NOC) from DCGI (the Indian Regulatory Authority) for the proposed oncology trial. The trial will be conducted by Dr. Ashok K. Vaid and his staff at the Department of Medical Oncology and Hematology at Medanta Medicity Hospital in Gurugram, India. The Hemopurifier® treatments will be performed by Dr. Puneet Sodhi from the Department of Nephrology, who has conducted more Hemopurifier® treatments than anyone else in the world.

 

"The approval from the MIEC, coming closely on the heels of our two ethics committee approvals in Australia, to conduct this early feasibility study, is another important step in our plan to evaluate use of the Hemopurifier as a treatment option in multiple tumor types, where cancer associated exosomes may promote immune suppression and metastasis,” stated Steven LaRosa, MD, Chief Medical Officer of Aethlon Medical. “We are very pleased that the MIEC accepted our study protocol and look forward to working, again, with Medanta Hospital with the expectation of recruiting patients in the fourth calendar quarter of this year. We believe that the planned safety, feasibility and dose finding trial, taking place in both India and Australia, in solid tumors in patients failing treatment with anti-PD-1 antibodies, will help inform future oncology efficacy trials.”

 

The primary endpoint of the approximately nine to 18-patient, safety, feasibility and dose-finding trial is safety. The trial will monitor any adverse events and clinically significant changes in lab tests of Hemopurifier treated patients with solid tumors with stable or progressive disease at different treatment intervals, after a two-month run in period of PD-1 antibody, Keytruda® or Opdivo® monotherapy. Patients who do not respond to the PD-1 therapy will be eligible to enter the Hemopurifier® period of the study where sequential cohorts will receive 1, 2 or 3 Hemopurifier® treatments during a one-week period. In addition to monitoring safety, the study is designed to examine the number of Hemopurifier® treatments needed to decrease the concentration of EVs and if these changes in EV concentrations improve the body’s own natural ability to attack tumor cells. These exploratory central laboratory analyses are expected to inform the design of a subsequent efficacy and safety, Premarket Approval (PMA), study required by regulatory agencies.

 

Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broad populations of cancer patients, recently announced positive initial response data from the first five patients treated with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel in first line pancreatic cancer as part of its ongoing Phase 2a clinical trial.

 

Highlights:

 

- In Phase 2a arm investigating IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel, complete or partial responses have been observed in the first two patients (2/5) to date, for an initial response rate of 40% and an initial disease control rate of 80%, with all five patients continuing on treatment -

 

- Initial data are at 240 mg QD (safety lead-in dose) of IMM-1-104; additional patients have now been dosed at 320 mg QD in this arm; IMM-1-104 has been well-tolerated to date in combination with gemcitabine/nab-paclitaxel -

 

- Initial data are consistent with preclinical data presented at AACR, which demonstrated that IMM-1-104 combined with chemotherapy induced deeper responses than either agent alone -

 

- Clear path forward expected for clinical development of IMM-1-104 in combination with gemcitabine/nab-paclitaxel for pancreatic cancer, assuming initial data is representative; FDA previously granted IMM-1-104 Fast Track designation for the treatment of first- and second-line pancreatic ductal adenocarcinoma -

 

- Enrollment progressing in all Phase 2a arms with further data expected by year end -

 

Continued from the news: “We are delighted to share today’s initial data on IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel. While the initial ORR of 40% and Disease Control Rate of 80% are very encouraging – and both more than would be expected for gemcitabine/nab-paclitaxel alone- we are still in the early stages of this trial, with more scans for all five of these initial patients and for additional patients planned to come. Nevertheless, it was encouraging to see a complete response in the very first pancreatic cancer patient treated with IMM-1-104 in this combination, with the patient now on treatment for over six months,” said Ben Zeskind, Ph.D., Co-Founder and CEO of Immuneering. “Looking at the bigger picture, our Phase 2a trial aims to evaluate the efficacy of IMM-1-104 in multiple settings across various tumor types, to identify the highest priority opportunities for future development. If the early trends with IMM-1-104 in combination with modified gemcitabine/nab-paclitaxel continue, we will have an exciting direction for potential future development of IMM-1-104, which could greatly improve the prognosis for a drastically underserved patient population.”

 

Earlier this year, Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, announced updated clinical data for lifileucel in combination with pembrolizumab in frontline advanced melanoma, as well as translational data, from the recent 2024 ASCO Annual Meeting held earlier this year in Chicago, IL and online.

 

Clinical Data in Frontline Advanced Melanoma (Cohort 1A in IOV-COM-202 Trial)

Positive results from Cohort 1A in the IOV-COM-202 trial were published in an abstract1 and will be highlighted in an upcoming oral presentation at ASCO. Unprecedented response rates, as well as deep and durable responses, were observed in patients with frontline advanced melanoma who were naïve to immune checkpoint inhibitor (ICI) therapy. These results strongly support the ongoing Phase 3 TILVANCE-301 clinical trial.

National Cancer Institute reported ”In an event more than three decades in the making, the Food and Drug Administration (FDA) has approved lifileucel (Amtagvi), the first treatment for cancer that uses immune cells called tumor-infiltrating lymphocytes, or TILs. Announced on February 16, the agency’s decision also makes lifileucel the first cellular therapy to be approved for a solid tumor, the skin cancer melanoma.”

 

Continued: “The agency’s accelerated approval covers the use of lifileucel for people with advanced melanoma that has gotten worse after treatment with certain immunotherapy drugs or targeted therapies.

 

Continued: “As is the case with CAR T-cell therapy, another type of cellular therapy, lifileucel is made using a patient’s own T cells. And with both therapies, the cells are collected at the hospital where the patient is being treated but are sent away to be manufactured into the final treatment.”

 

Also seeing the potential of immunotherapy, Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company announced last week that an agreement has been executed with QIMR Berghofer Medical Research Institute, one of Australia's foremost cancer research centres, to obtain an exclusive license to certain intellectual property rights in relation to combination therapies consisting of PI3K inhibitor drugs, and one or more immunotherapy or PARP inhibitor drugs (PI3K combination).

 

From the news: Under the license agreement, Kazia receives an exclusive, worldwide, sub-licensable and royalty-bearing licence to certain intellectual property for the development of any drugs or product candidates within the PI3K inhibitor class in combination with immunotherapy or PARP inhibitors. Paxalisib, Kazia's lead product candidate, is a member of the PI3K inhibitor class.

 

Continued: The exclusive license agreement follows a collaboration between Kazia and QIMR Berghofer which began in December 2022 and has already led to the filing of supportive patents which include the use of paxalisib as an immune modulator in the treatment of diseases such as breast cancer.

 

The idea of using a patient’s immune system to battle cancer makes sense and dollars for the companies that are pioneering this approach. Let the clinical trials begin!

 

Read part one of the series of articles at Investorideas.com

https://www.investorideas.com/News/2024/biotech/09170Solid-Tumors-Market.asp

 

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/Stock_List.asp

About Investorideas.com - Big Investing Ideas

Investorideas.com is the go-to platform for big investing ideas. From breaking stock news to top-rated investing podcasts, we cover it all. Our original branded content includes podcasts such as Exploring Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create free investor stock directories for sectors including mining, crypto, renewable energy, gaming, biotech, tech, sports and more. Public companies within the sectors we cover can use our news publishing and content creation services to help tell their story to interested investors. Paid content is always disclosed.

 

Disclaimer/Disclosure: This news article featuring AEMD is a paid for news release on Investorideas.com. Our site does not make recommendations for purchases or sale of stocks, services or products.  This is not investment opinion: Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services and prices on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

 

Follow us on X @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube https://www.youtube.com/c/Investorideas

 

Contact Investorideas.com

800-665-0411

 

Biotech Industry Stocks- investing ideas in biotechnology stocks, medical technology and life sciences

Get more biotech and medical tech news, articles, podcasts and stock directories